AU2004210671A1 - Enantiomeric amphetamine compositions for the treatment of ADHD - Google Patents
Enantiomeric amphetamine compositions for the treatment of ADHD Download PDFInfo
- Publication number
- AU2004210671A1 AU2004210671A1 AU2004210671A AU2004210671A AU2004210671A1 AU 2004210671 A1 AU2004210671 A1 AU 2004210671A1 AU 2004210671 A AU2004210671 A AU 2004210671A AU 2004210671 A AU2004210671 A AU 2004210671A AU 2004210671 A1 AU2004210671 A1 AU 2004210671A1
- Authority
- AU
- Australia
- Prior art keywords
- amphetamine
- isomer
- pharmaceutical combination
- release
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44579303P | 2003-02-10 | 2003-02-10 | |
| US60/445,793 | 2003-02-10 | ||
| US47392503P | 2003-05-29 | 2003-05-29 | |
| US60/473,925 | 2003-05-29 | ||
| PCT/US2004/003821 WO2004071501A1 (en) | 2003-02-10 | 2004-02-10 | Enantiomeric amphetamine compositions for the treatment of adhd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004210671A1 true AU2004210671A1 (en) | 2004-08-26 |
Family
ID=32871959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004210671A Abandoned AU2004210671A1 (en) | 2003-02-10 | 2004-02-10 | Enantiomeric amphetamine compositions for the treatment of ADHD |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040220277A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1626709B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006517232A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050119106A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE372112T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004210671A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2515394A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602004008771T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2293223T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004071501A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| EP1874274A2 (en) * | 2005-04-06 | 2008-01-09 | Mallinckrodt Inc. | Matrix-based pulse release pharmaceutical formulation |
| WO2007041571A1 (en) * | 2005-10-03 | 2007-04-12 | Cambrex Charles City, Inc. | Improved method of making amphetamine free base |
| ATE536867T1 (de) | 2006-03-16 | 2011-12-15 | Tris Pharma Inc | Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| US10463633B2 (en) * | 2010-04-23 | 2019-11-05 | Kempharm, Inc. | Therapeutic formulation for reduced drug side effects |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| WO2013059676A1 (en) * | 2011-10-21 | 2013-04-25 | Subhash Desai | Compositions for reduction of side effects |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| IL288554B2 (en) * | 2016-02-24 | 2024-02-01 | Chemapotheca LLC | Controlled release of amphetamine, drug meters and dosage forms with abuse deterrence |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| CA3221280A1 (en) | 2021-06-03 | 2022-12-08 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| CA3239514A1 (en) * | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6056968A (en) * | 1997-03-11 | 2000-05-02 | Darwin Discovery Limited | Pharmaceutical drug dosage forms providing different release rates |
| US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| WO2000059481A1 (en) * | 1999-04-06 | 2000-10-12 | Pharmaquest Ltd. | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT |
| TWI291871B (en) * | 2000-11-01 | 2008-01-01 | Cognition Pharmaceuticals Llc | Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning |
| AU2003208170B2 (en) * | 2002-02-28 | 2006-11-23 | Birseck Pty Ltd | Treatment of effect of chemicals with their ultradilute stereoisomers |
| AU2003231156A1 (en) * | 2002-04-30 | 2003-11-17 | Npd Llc | Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments |
| US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
-
2004
- 2004-02-10 US US10/774,697 patent/US20040220277A1/en not_active Abandoned
- 2004-02-10 WO PCT/US2004/003821 patent/WO2004071501A1/en not_active Ceased
- 2004-02-10 ES ES04709870T patent/ES2293223T3/es not_active Expired - Lifetime
- 2004-02-10 DE DE602004008771T patent/DE602004008771T2/de not_active Expired - Fee Related
- 2004-02-10 CA CA002515394A patent/CA2515394A1/en not_active Abandoned
- 2004-02-10 AT AT04709870T patent/ATE372112T1/de not_active IP Right Cessation
- 2004-02-10 AU AU2004210671A patent/AU2004210671A1/en not_active Abandoned
- 2004-02-10 EP EP04709870A patent/EP1626709B1/en not_active Expired - Lifetime
- 2004-02-10 JP JP2006503445A patent/JP2006517232A/ja active Pending
- 2004-02-10 KR KR1020057014628A patent/KR20050119106A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2293223T3 (es) | 2008-03-16 |
| KR20050119106A (ko) | 2005-12-20 |
| WO2004071501A1 (en) | 2004-08-26 |
| DE602004008771D1 (de) | 2007-10-18 |
| CA2515394A1 (en) | 2004-08-26 |
| HK1091117A1 (en) | 2007-01-12 |
| EP1626709B1 (en) | 2007-09-05 |
| DE602004008771T2 (de) | 2008-06-12 |
| ATE372112T1 (de) | 2007-09-15 |
| EP1626709A1 (en) | 2006-02-22 |
| US20040220277A1 (en) | 2004-11-04 |
| JP2006517232A (ja) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1626709B1 (en) | Enantiomeric amphetamine compositions for the treatment of adhd | |
| CA2499546C (en) | Sustained released delivery of amphetamine salts | |
| US9173857B2 (en) | Controlled dose drug delivery system | |
| EP2688557B1 (en) | Methods and compositions for treatment of attention deficit disorder | |
| CA2651890C (en) | Controlled dose drug delivery system | |
| US9289394B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
| US9023389B1 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
| US20170189342A1 (en) | Methods and Compositions for the Treatment of Seizure-Related Disorders | |
| US9034902B2 (en) | Methods for treatment of attention deficit hyperactivity disorder | |
| US9603809B2 (en) | Methods of treatment of attention deficit hyperactivity disorder | |
| JP2021506944A (ja) | 持続放出ミドドリン塩酸塩組成物及び使用方法 | |
| US20190060244A9 (en) | Methods of Treatment of Attention Deficit Hyperactivity Disorder | |
| US20220110878A1 (en) | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | |
| HK1091117B (en) | Enantiomeric amphetamine compositions for the treatment of adhd | |
| MXPA05008448A (en) | Enantiomeric amphetamine compositions for the treatment of adhd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: SHIRE CANADA INC. Free format text: FORMER NAME: SHIRE BIOCHEM INC. |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |